SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Manel Pladevall, Nuria Riera-Guardia, Andrea V Margulis, Cristina Varas-Lorenzo, Brian Calingaert, Susana Perez-Gutthann, Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies, BMC Cardiovascular Disorders, 2016, 16, 1

    CrossRef

  2. 2
    Scot H Simpson, Jayson Lee, Sabina Choi, Ben Vandermeer, Ahmed S Abdelmoneim, Travis R Featherstone, Mortality risk among sulfonylureas: a systematic review and network meta-analysis, The Lancet Diabetes & Endocrinology, 2015, 3, 1, 43

    CrossRef

  3. 3
    Elisabetta Patorno, Amanda R. Patrick, Elizabeth M. Garry, Sebastian Schneeweiss, Victoria G. Gillet, Dorothee B. Bartels, Elvira Masso-Gonzalez, John D. Seeger, Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations, Diabetologia, 2014, 57, 11, 2237

    CrossRef

  4. 4
    A. A. Ghotbi, L. Kober, N. Finer, W. P. T. James, A. M. Sharma, I. Caterson, W. Coutinho, L. F. Van Gaal, C. Torp-Pedersen, C. Andersson, Association of Hypoglycemic Treatment Regimens With Cardiovascular Outcomes in Overweight and Obese Subjects With Type 2 Diabetes: A substudy of the SCOUT trial, Diabetes Care, 2013, 36, 11, 3746

    CrossRef

  5. 5
    Christian Christiansen, Martin Johansen, Steffen Christensen, James M O’Brien, Else Tønnesen, Henrik Sørensen, Preadmission metformin use and mortality among intensive care patients with diabetes: a cohort study, Critical Care, 2013, 17, 5, R192

    CrossRef

  6. 6
    O. J. Phung, E. Schwartzman, R. W. Allen, S. S. Engel, S. N. Rajpathak, Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis, Diabetic Medicine, 2013, 30, 10
  7. 7
    B.H.R. Wolffenbuttel, M.M. van der Klauw, De nieuwe ADA/EASD-consensus type 2 diabetes en wat u daarvan moet weten, Nederlands Tijdschrift voor Diabetologie, 2012, 10, 4, 206

    CrossRef

  8. 8
    P.-J. Guillausseau, D. Lévy, M. Virally-Kévorkian, M. Laloi-Michelin, J. Bitu, D. Sène, J.-P. Kévorkian, Diabète de type 2, antidiabétiques oraux et complications cardiovasculaires, Médecine des Maladies Métaboliques, 2012, 6, 1, 38

    CrossRef

  9. You have free access to this content9
    Roy Eldor, Itamar Raz, Diabetes therapy-focus on Asia: second-line therapy debate: insulin/secretagogues, Diabetes/Metabolism Research and Reviews, 2012, 28,
  10. 10
    Giuseppe Paolisso, Matteo Monami, Raffaele Marfella, Maria Rosaria Rizzo, Edoardo Mannucci, Dipeptidyl Peptidase-4 Inhibitors in the Elderly: More Benefits or Risks?, Advances in Therapy, 2012, 29, 3, 218

    CrossRef

  11. 11
    Robert Klempfner, Jonathan Leor, Alexander Tenenbaum, Enrique Z Fisman, Ilan Goldenberg, Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease, Cardiovascular Diabetology, 2012, 11, 1, 60

    CrossRef

  12. 12
    A. S. Abdelmoneim, S. E. Hasenbank, J. M. Seubert, D. R. Brocks, P. E. Light, S. H. Simpson, Variations in tissue selectivity amongst insulin secretagogues: a systematic review, Diabetes, Obesity and Metabolism, 2012, 14, 2
  13. 13
    Muhammad Abdul-Ghani, Ralph A. DeFronzo, Roy Eldor, Combination therapy in type 2 diabetes mellitus,